Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373126 · ClinicalTrials.gov registry record · Phase 4
The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
A Phase 4 study, sponsored by North Suffolk Mental Health Association.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00373126 is a Phase 4 study that has completed, run by North Suffolk Mental Health Association. The registered enrollment target is 40 participants.
The verdict
NCT00373126, a Phase 4 study, has completed, sponsored by North Suffolk Mental Health Association.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
It has been suggested that patients with schizophrenia smoke in order to produce amelioration of dysfunctional dopaminergic pathways allowing them to experience pleasure and satisfaction and overcome anhedonia. No studies have assessed the effects of nicotine withdrawal on reward responsivity in patients with schizophrenia. The investigators believe that an understanding of this is crucial if improved treatments for nicotine dependence are to be developed for this patient population. If this group already has deficits in reward responsivity as a symptom of the disease then they may be particularly prone to the effects of nicotine withdrawal on reward systems. Smoking cessation may lead to a further decrease in their responsivity to pleasurable stimuli and worsening anhedonia. Treatments for smoking cessation may need to ameliorate any increased deficits if they are likely to be effective in patients with schizophrenia.
Interventions
- DRUG transdermal nicotine patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373126
The ClinicalTrials.gov registry entry for NCT00373126 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Suffolk Mental Health Association, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which transdermal nicotine patch is the first listed.
NCT00373126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373126 about?
NCT00373126 is a clinical study titled "The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia". It has been suggested that patients with schizophrenia smoke in order to produce amelioration of dysfunctional dopaminergic pathways allowing them to experience pleasure and satisfaction and overcome anhedonia. No studies have assessed the effects of nicotine withdrawal on reward responsivity in pat...
What is the current status of trial NCT00373126?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00373126?
The interventions under investigation include: transdermal nicotine patch (DRUG).
Who is sponsoring clinical trial NCT00373126?
This trial is sponsored by North Suffolk Mental Health Association, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.